

8/20/03

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: Not yet assigned		ATTY.'S DOCKET NO.: C1040.70012US00	
		FILING DATE: Herewith		CONFIRMATION NO.: Not yet assigned	
		APPLICANT: Heather Lynn DAVIS et al.			
		GROUP ART UNIT: 1632		EXAMINER: Not yet assigned	
Sheet	1	of	4		

U.S. PATENT DOCUMENTS

Examiner's Initials†	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
AMF	*A1	5,593,972		Weiner et al.	01/14/1997
	*A2	5,620,896		Herrmann et al.	04/15/1997
	*A3	5,643,578		Robinson et al.	07/01/1997
	*A4	5,714,316		Weiner et al.	02/03/1998
	*A5	5,736,524		Content et al.	04/07/1998
	*A6	5,814,617		Hoffman et al.	09/29/1998
	*A7	5,256,767		Salk et al.	10/26/1993
	*A8	5,256,553		Overell et al.	10/26/1993
	*A9	5,780,448		Davis	07/14/1998
	*A10	5,856,462		Agrawal	01/05/1999
	*A11	5,565,293		Gluck et al.	10/15/1999
	*A12	5,972,346		Hauser et al.	10/26/1999
	*A13	5,981,274		Tyrrell et al.	11/09/1999
	*A14	5,565,203		Glück et al.	10/15/1996
	*A15	5,972,346		Hauser et al.	10/26/1999
	*A16	5,679,647	B1	Carson et al.	10/21/1997
	*A17	5,804,566	B1	Carson et al.	09/08/1998
	*A18	5,830,877	B1	Carson et al.	11/03/1998
AMF	*A19	5,985,847	B1	Carson et al.	11/16/1999

FOREIGN PATENT DOCUMENTS

Examiner's Initials†	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
AMF	*B1	WO	93/15207	A1		08/05/1993	
	*B2	WO	88/06185	A1		08/25/1988	
	*B3	WO	92/06212	A1		04/16/1992	
	*B4	CA	1 169 793			06/26/1984	
	*B5	WO	90/11092	A1		10/04/1990	
AMF	*B6	WO	95/05853	A1		03/02/1995	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials†	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
AMF	*C1	Agrawal, S., et al., "Pharmacokinetics of Antisense Oligonucleotides", <i>Clin Pharmacokinet.</i> , 7-16, (1995)	
AMF	*C2	Cattaneo, R., et al., "Signals regulating hepatitis B surface antigen transcription", <i>Nature</i> , 305:336-338, (1983)	
AMF	*C3	Cowdery, J., et al., "Bacterial DNA Induces NK Cells to Produce IFN-γ In Vivo and Increases the Toxicity of Lipopolysaccharides" <i>Bacterial DNA...</i> , (1996)	

/Anne Marie Falk/ 10/15/2006

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: Not yet assigned	ATTY.'S DOCKET NO.: C1040.70012US00
		FILING DATE: Herewith	CONFIRMATION NO.: Not yet assigned
		APPLICANT: Heather Lynn DAVIS et al.	
		GROUP ART UNIT: 1632	EXAMINER: Not yet assigned
Sheet	2	of	4

OTHER ART—NON PATENT LITERATURE DOCUMENTS

Examiner's Initials†	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
AMF	*C4	Davis, H., et al., "Direct gene transfer into skeletal muscle in vivo: Factors affecting efficiency of transfer and stability of expression" <i>Human Gene Therapy</i> , 4: 151-159, (1993)	
	*C5	Davis, H., et al., "DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody" <i>Human Molecular Genetics</i> , 2:1847-1852, (1993)	
	*C6	Davis, H., et al., "DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines, <i>Proc Natl Acad Sci</i> , 93:7213-7218, (1996)	
	*C7	Fujieda, S., et al., "Effect of OK-432 on Cytotoxic Activity in Cancer patients without Tumor Burden", <i>Anticancer Research</i> , 12:1941-1946, (1992)	
	*C8	Fujisawa T et al, "Serial changes in titers of antibody to hepatitis B surface antigen after immunization of infants born to mothers with hepatitis B e antigen". <i>Pediatr. Gastroenterol Nutr</i> , 23:270-274, (1996)	
	*C9	Fuller, D., et al., "Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene Gun-mediated DNA vaccination", <i>J. Med. Primates</i> , 25:236-241, (1996)	
	*C10	Fynan, E., et al., "DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations", <i>Proc. Natl. Acad. Sci.</i> , 90:11478-11482, (1993)	
	*C11	Gao, W., et al., "Phosphorothioate Oligonucleotides are inhibitors of human DNA polymerases and Rnase H: implications for antisense technology", 223-229, (1991)	
	*C12	Jones, T., et al., "Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys", <i>Vaccine</i> , 17:3065-3071, (1999)	
	*C13	Karlin, S., et al., "Why is CpG Suppressed in the Genomes of Virtually All Small Eukaryotic Viruses but Not in Those of large Eukaryotic Viruses?", <i>Journal of Virology</i> , 2889-2897, (1994)	
	*C14	Kataoka, T., et al., "Antitumor Activity of Synthetic Oligonucleotides with Sequences from cDNA Encoding Proteins of Mycobacterium vobis BCG", <i>Jpn. J. Cancer Res.</i> , 83:244-247, (1992)	
	*C15	Krieg, A., et al., "CpG motifs in bacterial DNA trigger direct B-cell activation", <i>Nature</i> , 374:546-549, (1995)	
	*C16	Lee, P.I., et al., "Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen." <i>J. Pediatr</i> , 126: 716-721, (1995)	
	*C17	Li, Z., et al., "Desmin sequence elements regulating skeletal muscle-specific expression in transgenic mice", <i>Development</i> , 117:947-959, (1993)	
	*C18	LIU, H., et al., "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage colony-Stimulating Factor", <i>Blood</i> , 92:10:3730-3736, (1998)	
	*C19	LUTYNSKI R. and Juszczak R, "The level of anti-HBs in blood serum of persons selected from a group of Krakow inhabitants" <i>Folia Med. Cracov.</i> , 38: 63-68, (1997)	
↓	*C20	Mcintyre, K., et al., "A Sense Phosphorothioate Oligonucleotide Directed to the Initiation Codon of Transcription Factor NF-kB p65 Causes Sequence-Specific Immune Stimulation", <i>Antisense&Nucleic Acid Drug Development</i> , 3:309-322, (1993)	
AMF	*C21	MANZEL, L., et al., "Lack of Immune Stimulation by Immobilized CpG-Oligodeoxynucleotide", <i>Antisense&Nucleic Acid Drug Development</i> , 9:459-464, (1999)	

/Anne Marie Falk/ 10/15/2006

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: Not yet assigned		ATTY.'S DOCKET NO.: C1040.70012US00	
				FILING DATE: Herewith		CONFIRMATION NO.: Not yet assigned	
				APPLICANT: Heather Lynn DAVIS et al.			
				GROUP ART UNIT: 1632		EXAMINER: Not yet assigned	
Sheet	3	of	4				

OTHER ART —NON PATENT LITERATURE DOCUMENTS (continued)

Examiner's Initials†	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
AMF	*C22	MOJCIK, C., et al., "Administration of a Phosphorothioate Oligonucleotide Antisense Murine Endogenous Retroviral MCF env Causes Immune Effects in Vivo in a Sequence-Specific Manner", <i>Clinical Immunology and ImmunoPathology</i> , 67:2:130-136, (1993)	
	*C23	PISETSKY, D., et al., "Immunologic Consequences of Nucleic Acid Therapy", <i>Antisense & Nucleic Acid Drug Development</i> , 5:219-225, (1995)	
	*C24	PRINCE, A., et al., "Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus", <i>Vaccine</i> , 15:8:916-919, (1997)	
	*C25	RAZ, E., et al., "Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses", <i>Proc. Natl. Acad. Sci.</i> , 91:9515-9523, (1994)	
	*C26	ROBINSON, H., "Nucleic acid vaccines: an overview", <i>Vaccine</i> , 15:8:785-787, (1997)	
	*C27	SANDS, H., et al., "Biodistribution and Metabolism of Internally 3H-Labeled Oligonucleotides. I. Comparison of a Phosphodiester and a Phosphorothioate", <i>The American Society for Pharmacology</i> , 45:932-943, (1994)	
	*C28	STEIN, C., et al., "Antisense Oligonucleotides as Therapeutic Agents - Is the bullet Really Magical", <i>Science</i> , 261:1004-1012, (1993)	
	*C29	THOMSEN, D., et al., "Promoter-regulatory region of the major immediate early gene of human cytomegalovirus", <i>Proc. Natl. Acad. Sci.</i> , 81:659-663, (1984)	
	*C30	TOKUNAGA, T., et al., "Antitumor Activity of Deoxyribonucleic Acid Fraction From Mycobacterium bovis BCG. I. Isolation, Physicochemical Characterization, and Antitumor Activity", <i>JNCI</i> , 72:955-962, (1984)	
	*C31	ULMER, J., et al., "Heterologous protection Against Influenza by Injection of DNA Encoding a Viral Protein", <i>Science</i> , 259:1745-1749, (1993)	
	*C32	VALENZUELA, P., et al., "Synthesis and assembly of hepatitis B virus surface antigen particles in yeast", <i>Nature</i> , 298:347-350, (1982)	
	*C33	WANG, B., et al., "Gene inoculation generates immune responses against human immunodeficiency virus type 1", <i>Proc Natl. Acad. Sci.</i> , 90:4156-4160, (1993)	
↓	*C34	YASWEN, P., et al., "Effects of Sequences of Thioated Oligonucleotides on cultured Human Mammary Epithelial Cells", <i>Antisense Research and Development</i> , 3:67-77, (1993)	
AMF	*C35	ZELPHATI, O., et al., "Inhibition of HIV-1 Replication in Cultured Cells with Antisense Oligonucleotides Encapsulated in Immunoliposomes", <i>Antisense Research and Development</i> , 3:323-338, (1993)	
	*C36	MILICH et al.	
	*C37	SHIH et al.	
	*C38	HA YNES et al.	
	*C39	SZMUNESS et al.	
	*C40	BÖHM et al.	
AMF	*C41	CALANDRA, G.B. et al., Recommendations for Prevention of Hepatitis B with Vaccine, Hepatitis B Vaccines in Clinical Practice, Merck Research Laboratories, pages 1-16, 1993	
AMF	*C42	CHAMBON, P., ADN: sur la piste du vaccin génétique, <i>Sciences et Avenir</i> , September 1993, pages 22-25	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: Not yet assigned		ATTY.'S DOCKET NO.: C1040.70012US00	
				FILING DATE: Herewith		CONFIRMATION NO.: Not yet assigned	
				APPLICANT: Heather Lynn DAVIS et al.			
				GROUP ART UNIT: 1632		EXAMINER: Not yet assigned	
Sheet	4	of	4				


OTHER ART —NON PATENT LITERATURE DOCUMENTS (continued)

Examiner's Initials†	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
AMF	*C43	HAYES, J.R. et al., Particle-mediated nucleic acid immunization, <i>Journal of Biotechnology</i> 44, 1996, pages 37-42	
	*C44	KUHÖBER, A., et al. DNA Immunization Induces Antibody and Cytotoxic T Cell Responses to Hepatitis B Core Antigen in H-2 ^b Mice, <i>The American Association of Immunologists</i> , 1996, pages 3687-3695	
	*C45	LEBORGNE, S. et al., <i>In Vivo</i> Induction of Specific Cytotoxic T Lymphocytes in Mice and Rhesus Macaques Immunized with DNA	
	*C46	Vector Encoding an HIV Epitope Fused with Hepatitis B Surface Antigen, <i>Virology</i> 240, 304-315, 1998, Article No. VY978942	
	*C47	WOLFF et al., Direct Gene Transfer into Muse Muscle in Vivo, <i>Science</i> , Vol. 247, March 1990, pages 1465-1468	
	*C48	RAZ, E. et al., "Systemic immunological effects of cytokine genes injected into skeletal muscle", <i>Proc. Natl. Acad. Sci. USA</i> , May 1993, Pages 4523-4527, Vol. 90	
	*C49	TANG, D. et al., "Genetic immunization is a simple method for eliciting an immune response", <i>Nature</i> , March 12, 1992, Pages 152-154, Vol. 356	
AMF	*C50	CHATTERGOON et al., Genetic Immunization: A New Era in Vaccines and Immune Therapeutics, <i>FASEB Journal</i> , Vol. 11, pages 753-763.	

EXAMINER /Anne Marie Falk/	DATE CONSIDERED 10/15/2006
----------------------------	----------------------------

†EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/146,072, filed September 2, 1998 and now pending, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).



FORM PTO-1449a and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/644,267		ATTY. DOCKET NO.: C1040.70012US00			
				FILING DATE: August 20, 2003		CONFIRMATION NO.: 6263			
				APPLICANT: Heather L. Davis et al.					
				GROUP ART UNIT: 1632		EXAMINER: Falk Not yet assigned			
Sheet	1	of	1						

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
AMF	*A20	5,565,023		Gluck et al.	10-15-1996

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	

EXAMINER: /Anne Marie Falk/	DATE CONSIDERED: 10/15/2006
------------------------------------	------------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

53 06 22

12/6/04

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/644,267		ATTY. DOCKET NO.: C1040.70012US00		
				FILING DATE: August 20, 2003		CONFIRMATION NO.: 6263		
				APPLICANT: Davis et al.				
				GROUP ART UNIT: 1632		EXAMINER: Falk Not Yet Assigned		
Sheet	1	of	1					

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
AMF	A21	5,817,637		Weiner et al.	10-06-1998
AMF	A22	5,830,876		Weiner et al.	11-03-1998

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
AMF	C51	DAVIS et al., Chapter 18: DNA-based immunization. <i>in</i> Molecular and Cell Biology of Human Gene Therapeutics. George Dickson, ed., 1995: p368-87. (ISBN: 0 412 62550 4)		
AMF	C52	HAHM et al., Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B. <i>Int J Immunopharmacol.</i> 1994 Mar;16(3):217-25.		
AMF	C53	LIU et al., Immunization of non-human primates with DNA vaccines. <i>Vaccine.</i> 1997 Jun;15(8):909-12.		
AMF	C54	MICHEL et al., DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. <i>Proc Natl Acad Sci U S A.</i> 1995 Jun 6;92(12):5307-11.		
AMF	C55	STAATS et al., Mucosal immunity to infection with implications for vaccine development. <i>Curr Opin Immunol.</i> 1994 Aug;6(4):572-83. Review.		

EXAMINER: /Anne Marie Falk/	DATE CONSIDERED: 10/15/2006
------------------------------------	------------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]